Instructions for Carboderm-Darnitsa cream 100 mg/g tube 30 g
Composition
active ingredient: urea;
1 g of cream contains 100 mg of urea;
excipients: cetylpyridinium chloride, propylene glycol, mineral oil, cetostearyl alcohol, purified water.
Dosage form
Cream.
Main physicochemical properties: homogeneous, white, odorless cream.
Pharmacotherapeutic group
Preparations with emollient and protective effects. Urea. ATX code D02A E01.
Pharmacological properties
Pharmacodynamics
Carboderm-Darnitsa® cream has a hydrating, keratolytic, antipruritic, antibacterial and antifungal effect. As a result of using the cream, the manifestations of hyperkeratosis are reduced, the skin is softened and moisturized, its elasticity is increased, and the epithelization of surface lesions is improved. Urea at a concentration of 10% has a bactericidal and fungicidal effect due to cetylpyridinium chloride, which is part of the drug. Due to the weak local anesthetic effect of urea, the drug has an antipruritic effect.
Pharmacokinetics
High-molecular polymeric substances of the ointment base retain urea on the surface of the application site, preventing its transdermal absorption, due to which urea does not enter the systemic bloodstream.
Indication
For the treatment of skin diseases accompanied by increased formation of keratinized epithelium.
The drug is used to treat psoriasis (in the stationary stage with significant infiltration), seborrhea, keratomycosis, hyperkeratosis, hyperkeratic forms of eczema, and ichthyosis.
Contraindication
The use of Carboderm-Darnitsa® cream is contraindicated in cases of increased individual sensitivity to urea or other components of the cream, as well as in dermatoses accompanied by severe exudation.
Interaction with other medicinal products and other types of interactions
There is no information on the interaction of Carboderm-Darnitsa® cream with other drugs, however, it should be borne in mind that simultaneous use of the cream with other ointments or creams may lead to increased absorption of the medicinal substances contained in them (especially corticosteroids).
The simultaneous use of other medicines containing urea and its derivatives is not recommended.
Application features
Avoid contact with eyes and mucous membranes.
To prevent exposure to healthy tissue, it is advisable to apply the cream without going beyond the affected area.
Do not use to treat acute inflammation of damaged skin.
Propylene glycol may cause skin irritation.
Cetostearyl alcohol may cause local skin reactions (e.g. contact dermatitis).
Ability to influence reaction speed when driving vehicles or other mechanisms
The drug does not affect the reaction speed when driving or working with other mechanisms.
Use during pregnancy or breastfeeding
The medicine should be used during pregnancy or breastfeeding as prescribed by a doctor.
Method of administration and doses
The medicine should be used to treat adults.
The doctor prescribes the dose of the cream individually depending on the type of disease, the degree of damage and the size of the affected area. The cream (on average, a strip 1–4 cm long) should be applied in a thin layer to the affected area of the skin 2 times a day. To increase the effectiveness of the treatment, occlusive dressings can be used.
The duration of treatment, which can be an average of 1–2 weeks, is determined by the doctor individually depending on the type and severity of the disease, taking into account the regression of symptoms of infiltration and lichenification of the skin.
Children
The drug should not be prescribed to children due to lack of clinical experience.
Overdose
No cases of overdose of the drug Carboderm-Darnitsa® have been recorded.
If a large amount of the medicine is accidentally swallowed and symptoms of intoxication occur, you should consult a doctor.
Adverse reactions
In rare cases, dermatological reactions may develop: skin redness, itching, tingling and skin irritation. Local allergic reactions, including contact dermatitis, are possible.
Occasionally, a burning sensation may occur, which more often occurs when applying an occlusive dressing.
If any adverse reactions occur, you should stop using the medicine and consult a doctor.
Expiration date
2 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
30 g in a tube; 1 tube in a pack.
Vacation category
Without a prescription.
Producer
PrJSC "Pharmaceutical Company "Darnitsa".
Location of the manufacturer and its business address
Ukraine, 02093, Kyiv, Boryspilska St., 13.
